Structure Therapeutics (GPCR) Net Cash Flow (2022 - 2026)

Structure Therapeutics' Net Cash Flow history runs 5 years deep, the most recent figure standing at -$483.5 million for Q1 2026.

• In Q1 2026, Net Cash Flow fell 2680.55% year-over-year to -$483.5 million; the TTM figure through Mar 2026 stood at $164.0 million (up 202.16% YoY), while the FY2025 annual figure was $630.1 million, up 1486.47% from the prior year.
• Net Cash Flow was -$483.5 million for Q1 2026 at Structure Therapeutics, down from $696.7 million in the prior quarter.
• In the past five years, Net Cash Flow ranged from a high of $696.7 million in Q4 2025 to a low of -$483.5 million in Q1 2026.
• Historically, Net Cash Flow has averaged $12.4 million across 5 years, with a median of -$5.1 million in 2025.
• The sharpest annual moves came in 2025 and 2026: Net Cash Flow surged 26692.02% in 2025, then sank 2680.55% in 2026.
• A 5-year view of Net Cash Flow shows it stood at -$2.0 million in 2022, then surged by 4055.82% to $79.2 million in 2023, then plunged by 103.31% to -$2.6 million in 2024, then soared by 26692.02% to $696.7 million in 2025, then sank by 169.39% to -$483.5 million in 2026.
• The last three Net Cash Flow figures came in at -$483.5 million (Q1 2026), $696.7 million (Q4 2025), and -$44.1 million (Q3 2025), per Business Quant data.